clinical trial · NCT06370715
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
Eli Lilly and Company·phase4·completed·n = 150
Diabetes Mellitus, Type 2Insulin Lispro-aabcInsulin Glargine
brief summary
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
started
Apr 18, 2024
primary completion
Sep 2, 2025
completion
Sep 2, 2025
last updated
Oct 16, 2025
official title
A 26- Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol